Bristol-Myers Squibb Co (BMY) Shares Bought by D.A. Davidson & CO.

D.A. Davidson & CO. grew its position in Bristol-Myers Squibb Co (NYSE:BMY) by 2.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 209,486 shares of the biopharmaceutical company’s stock after acquiring an additional 5,116 shares during the quarter. D.A. Davidson & CO.’s holdings in Bristol-Myers Squibb were worth $11,593,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Hunter Associates Investment Management LLC boosted its position in Bristol-Myers Squibb by 4.4% during the 4th quarter. Hunter Associates Investment Management LLC now owns 18,488 shares of the biopharmaceutical company’s stock valued at $1,133,000 after purchasing an additional 780 shares during the period. DnB Asset Management AS boosted its position in Bristol-Myers Squibb by 0.3% during the 2nd quarter. DnB Asset Management AS now owns 321,762 shares of the biopharmaceutical company’s stock valued at $17,806,000 after purchasing an additional 900 shares during the period. Gillespie Robinson & Grimm Inc. boosted its position in Bristol-Myers Squibb by 12.3% during the 2nd quarter. Gillespie Robinson & Grimm Inc. now owns 8,679 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 950 shares during the period. Canandaigua National Bank & Trust Co. boosted its position in Bristol-Myers Squibb by 1.8% during the 1st quarter. Canandaigua National Bank & Trust Co. now owns 56,569 shares of the biopharmaceutical company’s stock valued at $3,578,000 after purchasing an additional 995 shares during the period. Finally, Crescent Grove Advisors LLC boosted its position in Bristol-Myers Squibb by 6.8% during the 2nd quarter. Crescent Grove Advisors LLC now owns 15,657 shares of the biopharmaceutical company’s stock valued at $866,000 after purchasing an additional 1,000 shares during the period. Institutional investors and hedge funds own 71.39% of the company’s stock.

Shares of Bristol-Myers Squibb opened at $59.53 on Friday, Marketbeat Ratings reports. The company has a quick ratio of 1.28, a current ratio of 1.40 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $96.41 billion, a PE ratio of 17.45, a PEG ratio of 1.49 and a beta of 1.02. Bristol-Myers Squibb Co has a fifty-two week low of $49.96 and a fifty-two week high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $1.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.14. The business had revenue of $5.70 billion during the quarter, compared to analyst estimates of $5.48 billion. Bristol-Myers Squibb had a return on equity of 42.58% and a net margin of 1.74%. The company’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.74 earnings per share. equities analysts anticipate that Bristol-Myers Squibb Co will post 3.62 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 1st. Stockholders of record on Friday, July 6th were issued a $0.40 dividend. The ex-dividend date of this dividend was Thursday, July 5th. This represents a $1.60 annualized dividend and a dividend yield of 2.69%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 53.16%.

BMY has been the subject of a number of analyst reports. Jefferies Financial Group restated a “hold” rating and set a $66.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, April 13th. Morgan Stanley lowered Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $54.08 to $58.00 in a research report on Tuesday, April 17th. William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, April 17th. Bank of America reduced their price target on Bristol-Myers Squibb from $68.00 to $61.00 and set a “neutral” rating for the company in a research report on Tuesday, April 17th. Finally, Credit Suisse Group set a $58.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Tuesday, April 17th. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $63.11.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Featured Story: Are analyst ratings accurate?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply